Pharscin Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 72.4556 million yuan, a year-on-year decrease of 2.84%

According to the Zhitong Finance APP, Pharscin Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 626 million yuan, a year-on-year increase of 1.90%. The net profit attributable to shareholders of the listed company was 72.4556 million yuan, a year-on-year decrease of 2.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 52.2035 million yuan, a year-on-year decrease of 13.03%